Creo Medical Group PLC
OTC:CMEOF

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
OTC:CMEOF
Watchlist
Price: 0.2 USD Market Closed
Market Cap: $82.5m

Wall St Price Targets

CMEOF Price Targets Summary
Creo Medical Group PLC

Wall Street analysts forecast CMEOF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CMEOF is 0.72 USD with a low forecast of 0.57 USD and a high forecast of 1.04 USD.

Lowest Forecast
Price Target
0.57 USD
186% Upside
Average Forecast
Price Target
0.72 USD
261% Upside
Highest Forecast
Price Target
1.04 USD
420% Upside
Creo Medical Group PLC Competitors:
Price Targets
XPEL
Xpel Inc
18% Upside
558
LK Technology Holdings Ltd
59% Upside

Revenue
Forecast

N/A
Past Growth
63% / Year
Estimated Growth
Estimates Accuracy
-44%
Average Miss
N/A
Past Growth
63% / Year
Estimated Growth
Estimates Accuracy
-44%
Average Miss

The compound annual growth rate for Revenue over the next 6 years is 63%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
16%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
16%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CMEOF's stock price target?
Price Target
0.72 USD

According to Wall Street analysts, the average 1-year price target for CMEOF is 0.72 USD with a low forecast of 0.57 USD and a high forecast of 1.04 USD.

What is the Revenue forecast for Creo Medical Group PLC?
Projected CAGR
63%

The compound annual growth rate for Revenue over the next 6 years is 63%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett